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REDUCTASE AND DIHYDROPTEROATE SYNTHASE MUTATIONS IN
MONITORING IN VIVO RESISTANCE
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Abstract. Prior to the 2001 malarial treatment policy change in Tanzania, we conducted trials to assess the efficacy
of sulfadoxine-pyrimethamine (SP) and the usefulness of molecular markers in monitoring resistance. A total of 383
uncomplicated Plasmodium falciparum malaria patients (between 6 and 59 months old) were treated with SP and their
responses were assessed. Mutations in the P. falciparum dihydrofolate reductase (pfdhfr) and dihydropteroate synthase
(pfdhps) genes in admission day blood samples were analyzed. Results indicated that 85.6% of the patients showed an
adequate clinical response, 9.7% an early treatment failure, and 4.7% a late treatment failure. The quintuple mutant
genotype (pfdhfr 51 Ile, 59 Arg, and 108 Asn and pfdhps 437 Gly and 540 Glu) showed an association with treatment
outcome (odds ratio 2.1; 95% confidence interval 0.94–4.48, P 0.045). The prevalence of the triple pfdhfr mutant
genotype (51 Ile, 59 Arg, and 108 Asn) at a site of high SP resistance (23.6%) was four times higher compared with that
observed at sites of moderate SP resistance (6.8−14.4%) (P 0.000001). The genotype failure index calculated by using
this marker was invariable (1.96−2.1) at sites with moderate SP resistance, but varied (3.4) at a site of high SP resistance.
In conclusion, our clinical and molecular findings suggest that SP may have a short useful therapeutic life in Tanzania;
thus, its adoption as an interim first-line antimalarial drug. The findings also point to the potential of the triple pfdhfr
mutant genotype as an early warning tool for increasing SP resistance. These data form the baseline SP efficacy and
molecular markers profile in Tanzania prior to the policy change.
INTRODUCTION
In 2001, the Tanzania mainland adopted sulfadoxine-
pyrimethamine (SP) and amodiaquine (AQ) as first- and sec-
ond-line antimalarial drugs, respectively, following increased
chloroquine (CQ) resistance (45–70%). The use of SP for
first-line purposes is an interim measure while different anti-
malarial combinations are being evaluated for long-term use.
Before this change, SP was used as a second-line antimalarial
drug.1 Several other countries in southern Africa including
Kenya, Burundi, Rwanda, the Tanzania islands (Zanzibar),
and Malawi have switched to SP, AQ, or artesunate (AS)
monotherapies or combination therapies, whereas Uganda
opted for the SP/CQ combination following widespread CQ
resistance.2 Sulfadoxine-pyrimethamine is one of the few,
cheap, and relatively safe antimalarial drugs that is still effec-
tive against CQ-resistant malaria in Africa. Recent studies in
southern Africa have recorded high efficacies, ranging from
82% to 92%.2–8 However, the fact that Plasmodium falci-
parum rapidly develops resistance to SP following wide use of
the drug poses a serious threat to malarial control efforts in
endemic countries.9 High levels of SP resistance have been
recorded in a highly endemic northeastern part of Tanzania
where pyrimethamine10,11 and sulfadoxine12 were used at dif-
ferent periods between 1950 and 1994 for prophylactic and
therapeutic trials, respectively. In a recent study conducted in
this area, 45% of the patients treated with SP failed to clear
their parasitemias to below patency levels on day 7.13 This
failure rate is substantially higher compared with 25% in
Ifakara (southeastern Tanzania)14 and 26% in Kigoma (west-
ern Tanzania),5 both of which are also highly endemic areas
in Tanzania, but in which SP had not been widely used.
Therefore, it is obvious that following wide use of SP in Tan-
zania, resistance is likely to increase rapidly. Given appropri-
ate tools, the National Malaria Control Program (NMCP)
framework provides a better platform for regularly updating
information on antimalarial drug resistance situation in Tan-
zania. Currently, the in vivo efficacy test is the gold standard
method for monitoring antimalarial drug resistance in coun-
tries endemic for malaria. However, the method is expensive
and complex in terms of interpreting outcomes, especially in
high transmission areas where chances of re-infection are
high. Thus, the need for a cheap, rapid, and reliable epide-
miologic tool for SP surveillance has been recognized.
Molecular markers of SP resistance are considered to be a
cheap and less complex candidate tool for in vivo SP resis-
tance surveillance. There is a large body of data showing that
a combination of mutations in the P. falciparum dihydrofolate
reductase (pfdhfr) (51 Ile, 59 Arg, and 108 Asn) and dihy-
dropteroate synthase (pfdhps) (437 Gly and 540 Glu) genes
might constitute a useful marker for field surveillance of SP
resistance in Africa.15–24 However, the usefulness of these
markers remains controversial because other investiga-
tors25,26 did not establish an association with treatment out-
come. Furthermore, some new mutations in the pfdhfr gene
have been discovered27; thus, their roles in vivo resistance
must be assessed. New approaches for understanding the re-
lationship between mutations and antimalarial drug resis-
tance have been suggested. The genotype resistance index
(GRI) and the genotype failure index (GFI) concepts28 and
the ratio of mutant to wild-type pfcrt alleles29 have been
pointed out as practical models using a pfcrt 76 Thr mutation
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in the surveillance of CQ resistance. There is a need to verify
such models (by using the pfdhfr and pfdhps gene markers) in
areas where SP is used as the first-line antimalarial drug.
As a preparation for the policy change, we conducted stud-
ies to determine SP efficacy and prevalence of SP resistance
molecular markers (pfdhfr and pfdhps gene mutations) in
Tanzania. We also assessed the applicability of these markers
in monitoring SP resistance. The findings presented here form
the baseline SP efficacy and molecular markers profile for
Tanzania and support the decision made by the Ministry of
Health to adopt SP as an interim first-line antimalarial drug.
Our findings also present evidence of association between
treatment failure and quintuple mutant genotype. The preva-
lence of mutant genotypes and GFI values in high versus
moderate resistance sites point to the potential of the triple
pfdhfr mutant genotype as an early warning tool for increas-
ing SP resistance in Tanzania. Nonetheless, we recommend
further studies, at both community and health facility levels,
to verify the usefulness of pfdhfr and pfdhps genotypes in
estimating SP resistance.
MATERIALS AND METHODS
Study sites. These trials were carried out in Butimba,
Kyela, Masasi, Mkuzi, and Mlimba Rural Health Centers in
Tanzania. These areas are antimalarial drug resistance sur-
veillance sites of the NMCP, classified epidemiologically
as mesoendemic (Kyela and Butimba) or holoendemic
(Mkuzi, Mlimba, and Masasi), and are located in different
geographic areas in the country (Figure 1). The catchment
areas for these health facilities are rural-based communities
of similar socioeconomic background.
Recruitment of study subjects. All patients between 6 and
59 months old who reported to the health centers were evalu-
ated and considered for recruitment by the study team. De-
tailed medical histories were obtained and clinical examina-
tions were conducted. Thick and thin smears were made from
finger prick blood and stained with Giesmsa for parasite de-
tection and identification by microscopy. Patients were even-
tually recruited for study if they had an axillary temperature
 37.5°C, microscopically confirmed P. falciparum monoin-
FIGURE 1. Map of Tanzania showing the geographic location of the study sites, resistance to sulfadoxine-pyrimethamine (S), and the
prevalence of Plasmodium falciparum dihydrofolate reductase (pfdhfr) and dihydropteroate synthase (pfdhps) genotypes. The triple pfdhfr (51
Ile, 59 Arg, and 108 Asn) and double pfdhps (437 Gly and 540 Glu) mutant genotypes are highly prevalent in Mkuzi, an area with the highest
level of resistance to SP. The rest of the sites (Butimba, Kyela Masasi, and Mlimba) have moderate levels of resistance to SP and prevalences of
this mutant genotype, but high prevalences of wild-type genotype. This figure appears in color at www.ajtmh.org.
AN EARLY WARNING TOOL FOR SP RESISTANCE 697
fections (parasitemia between 2,000 and 100,000 asexual stage
parasites/L), no history of antimalarial use in the last 14 days
prior to the episode, an absence of co-infection with other
diseases, and consent from parents or guardians. Patients who
had mixed Plasmodium spp. infections, severe malaria or dan-
ger sings, history of allergy to sulfa drugs, or other chronic
infections were not recruited for study but, respectively, were
given appropriate treatment by the study team.
Treatment of patients. Recruited patients were treated with
SP (Fansidar, 500 mg of sulfadoxine and 25 mg of pyrimeth-
amine; Roche, Basel, Switzerland) in a single oral dose of 1.25
mg/kg of pyrimethamine and 25 mg/kg of sulfadoxine and
observed for 30 minutes. If vomiting occurred within this pe-
riod, a replacement dose was administered and again ob-
served for an additional 30 minutes. Further vomiting led to
exclusion of the patient from the study. These patients were
rescued by parenterally administered quinine (nine doses of
30 mg/kg). Parents or guardians of recruited children were
asked to return to the health centers for response evaluation
on days 2, 3, 7, and 14 post-treatment. In addition, they were
advised to return at any other (unscheduled) day if tempera-
ture or sickness persisted or relapsed. Patients who did not
turn up for scheduled follow-ups were visited at home by a
member of the study team. Clinical and parasitologic exami-
nations were conducted on each follow-up day. A patient was
withdrawn from the study if any of the following occurred
during the follow-up period: development of a concurrent
infection, treatment with another antimalarial drug, the pa-
tient could not be traced at a home visit on a scheduled day or
the day after, or the parent/guardian requested that the pa-
tient be withdrawn from the study. Treatment responses were
classified as an adequate clinical response (ACR), an early
treatment failure (TF), and a late treatment failure (LTF) as
described in the 1996 World Health Organization (WHO) in
vivo efficacy testing protocol for areas of intense transmis-
sion.30 Patients who failed to respond were treated with amo-
diaquine (10 mg/kg for dose 1 and 2 and 5 mg/kg for dose 3).
At the end of the study, 414 patients were recruited (67 in
Butimba, 70 in Kyela, 78 in Masasi, 133 in Mkuzi, and 66 in
Mlimba). Thirty-one cases were either lost to follow-up or
excluded from the study during follow-up. Thus, 383 patients
completed the study or were followed-up to day of failure.
The study was reviewed and approved by the both institu-
tional (Ifakara Health Research and Development Centre
[IHRDC] Ethics Committee) and national (Medical Research
Coordinating Committee) authorities and consent was ob-
tained from parents or guardians prior to recruitment of each
patient.
Blood sample collection, extraction of DNA, and mutation
analysis. Before treatment of recruited patients, finger prick
blood was spotted onto filter paper (3MM; Whatman Inter-
national Ltd., Maidstone, United Kingdom), air-dried, trans-
ported to the IHRDC laboratory, and stored dry in self-
sealing plastic bags at room temperature until required for
extraction of DNA. The DNA was extracted from the filter
paper using the Chelex extraction method previously de-
scribed.31 Polymorphisms in pfdhfr codons 51, 59, 108, and
164 and pfdhps codons 436, 437, 540, 581, and 613 were de-
termined by performing primary and nested polymerase chain
reaction (PCR) amplifications with subsequent restriction
fragment length polymorphism (RFLP) analysis of the nested
PCR products as described in detail elsewhere.32 The RFLP
products were resolved by electrophoresis on 10% polyacryl-
amide gels, stained with ethidium bromide, photographed,
and scored. A 2 × 2 chi-square table was used to analyze
associations between clinical and molecular data and Epitable
in Epi-Info (Centers for Disease Control and Prevention, At-
lanta, GA and World Health Organization, Geneva, Switzer-
land) and was used to compare differences in the prevalence
of SP resistance and molecular markers in the study sites. P
values < 0.05 (and confidence intervals [CIs] > 1 for odds ratio
[OR]) were considered significant. The GFI was calculated as
the ratio of the prevalence of resistant genotype to the preva-
lence of drug failure,28 and the variability of the values among
study sites was assessed by linear regression.
RESULTS
Treatment outcome for SP and association with the quin-
tuple mutant genotype. Of 383 SP treated patients, 328
(85.6%) showed ACR with highest level of efficacy (93%)
being recorded in Butimba and the lowest (76.4%) in Mkuzi.
Fifty-five (14.4%) cases did not respond to SP treatment of
which 37 (9.7%) and 18 (4.7%) were ETF and LTF cases,
respectively (Table 1). There was no significant difference in
the prevalence of SP treatment failure in Butimba, Kyela,
Masasi, and Mlimba (2  2.52, degree of freedom [df]  3,
P  0.4723), but significant difference was observed (2 
15.06, df  4, P  0.0046) when the Mkuzi Health Center
was included in the analysis. Table 2 relates the clinical and
molecular data for the SP-treated patients. Of 55 treatment
failure cases 12 (22%) and 43 (78%) carried parasites with
quintuple and non-quintuple genotypes, respectively. Of the
328 patients who showed ACR, 39 (12%) and 289 (88%)
individuals harbored the quintuple and non-quintuple (any
other combination of genotypes apart from quintuple) geno-
types, respectively. Statistical analysis showed association be-
tween the quintuple mutant genotype and SP treatment fail-
ure (OR  2.1, 95% CI  0.94–4.48, P  0.045). Although
the lower 95% CI was slightly less than 1, a Pearson chi-
square test (2  4.0) indicated that this represented a sta-
tistically significant association (Table 2). In a separate analy-
sis, the triple pfdhfr mutant and the double pfdhps mutant
genotype did not show a predictive value for SP treatment
failure.
Prevalence of multiple pfdhfr and pfdhps mutant genotypes
and estimated GFI values. The prevalence of SP resistance
and pfdhfr and pfdhps genotypes is summarized and shown in
Figure 1. Mkuzi showed highest prevalence of triple pfdhfr
(80.3%) and double pfdhps (32.3%) mutant genotypes, while
TABLE 1
Summary of sulfadoxine-pyrimethamine treatment outcome in the
five sentinel sites in Tanzania*
Site No. ETF LTF Overall TF ACR
Butimba 57 4 0 4 (7%) 53 (93%)
Kyela 67 5 3 8 (12%) 59 (88%)
Masasi 73 4 1 5 (6.8%) 68 (92.9%)
Mkuzi 127 21 9 30 (23.6%) 97 (76.4%)
Mlimba 59 3 5 8 (13.5%) 51 (86.5%)
Total 383 37 (9.7%) 18 (4.7%) 55 (14.4%) 328 (85.6%)
* ETF  early treatment failure; LTF  late treatment failure; TF  treatment failure;
ACR  adequate clinical response.
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Mlimba showed the lowest prevalences of 18.6% and 3.4%,
respectively. There was no difference in the prevalence of the
triple pfdhfr mutant genotype (2 0.12, df 3, P 0.9893)
at the Butimba, Kyela, and Masasi, and Mlimba sites. How-
ever, a significant difference (2 131, df 4, P 0.000001)
are observed when the Mkuzi site was included in the analy-
sis. Conversely, the prevalence of the double pfdhps mutant
genotype was significantly different (2  12, df  3,
P  0.0074) at the Butimba, Kyela Masasi, and Mlimba sites
and more so (2  39, df 4, P 0.00012) when Mkuzi was
included in the analysis. Similarly, the prevalence of pure wild
pfdhfr and pfdhps genotypes was different among the low
resistance sites (2  12.3, df  3, P  0.006345 and 2 
49.4, df 3, P 0.00011, respectively). Using the prevalence
of different combinations of mutations in pfdhfr and pfdhps
as a marker for SP resistance, we calculated the GFI and
observed that only the triple pfdhfr mutant genotype gener-
ated invariable indices (ranging from 1.96 to 2.1) in moderate
resistance areas (Butimba, Kyela, Masasi, and Mlimba), sug-
gesting a relationship between the marker and SP treatment
failure. The GFI observed in Mkuzi (a high resistance area)
was 3.4, which was different from that observed in other sites.
Indices derived by other markers (combination of triple and
double pfdhfr or double pfdhps mutant genotypes) are highly
variable (Table 3) and do not suggest any relationship with
treatment failure. We did not detect pfdhps 436 Ala/Phe, 581
Gly, and 613 Thr/Ser and pfdhfr 164 Leu mutations in any of
our study sites.
DISCUSSION
In 2001, Tanzania-mainland adopted SP as an interim, first-
line antimalarial drug. As a preparation for this policy change,
we conducted studies to establish the baseline SP efficacy and
prevalence of SP resistance molecular markers (pfdhfr and
pfdhps mutations) in this country. We have established that
SP was effective against uncomplicated malaria when the
mainland of Tanzania revised its malaria treatment policy.
The ACR ranged from 76.4% to 93% (average efficacy 
85.6%), which was similar to efficacies reported in other
southern and eastern Africa countries (82–98%) between
1997 and 2002.2–8 In our trials, Mkuzi showed highest levels of
overall SP resistance (23.6%) followed by Mlimba (13.5%),
Kyela (12%), Butimba (7%), and Masasi (6.8%), with aver-
age resistance being 14.4%. According to the criteria for
changing malaria treatment policy,33,34 by 2000 resistance in
all sentinel sites had gone beyond the grace period (combined
ETF and LTF < 5%) and all except Mkuzi were within the
alert period (combined ETF and LTF between 6% and 15%).
It is interesting to note that before the policy change, SP
resistance in Mkuzi was already in the action period (com-
bined ETF and LTF between 16% and 24%). In 2001, the SP
parasitological failure rate by day 28 in the Muheza District
(in which the Mkuzi site is located) was 45%.13 So far this is
the area with the highest SP resistance in Tanzania. The
prevalent SP resistance observed in these studies is attribut-
able to the country-wide use of SP in the last several years as
a second-line antimalarial drug. However, the higher preva-
lence in Mkuzi is also due to the use of pyrimethamine for
prophylactic and/or therapeutic trials at different periods
from 1950s to 199410–12 and to the use of SP since 1984 for
first-line treatment in children less than five years of age at
the Muheza District Hospital.13 Thus, with the deployment of
SP for country-wide use, it is obvious that resistance will in-
crease rapidly. Therefore, our findings support the decision to
adopt SP as an interim, first-line, antimalarial drug, while
some combination antimalarials are being evaluated for long-
term use. High levels of SP resistance have also been ob-
served in the neighboring countries of Burundi and Rwanda,
with failure rates beyond the critical 25% value in most sen-
tinel sites. These countries have already switched to SP/AQ
and AQ/AS, respectively, as their first-line antimalarial
drugs.2
In this study, the quintuple mutant genotype was associated
(OR  2.1) with SP treatment failure by day 14. In previous
studies in Uganda23 and Malawi,24 stronger associations (OR
> 10) between treatment failure and pfdhfr 59 Arg and pfdhps
540 Glu mutations (the quintuple mutant predictors) were
observed. The smaller OR value observed in our study is
partly attributable to a shorter (14 days) follow-up period
used in this study. The majority of the SP treatment failure
cases are known to occur beyond day 14. Therefore, extended
follow-ups with subsequent distinction of recrudescence by
genotyping would have provided more reliable interpretation
of treatment response35 and improved the association.23 In
addition, inclusion of in vitro data would have been of para-
mount importance in elucidating the reason for the smaller
OR value and providing a wider SP efficacy baseline data for
Tanzania.
Our study has established that the prevalence of the triple
pfdhfr mutant genotype was four times higher in an area of
high SP resistance compared with areas of moderate SP re-
sistance. This observation clearly suggests a relationship be-
tween the marker and SP resistance, and points to the poten-
tial of this genotype in the development of a reliable early
warning tool for escalating SP resistance in Tanzania. The
GFI calculated by using this marker also varied between high
(3.4) and moderate SP resistance (1.96−2.1) sites. Nonethe-
less, values observed in the later sites are invariable and com-
parable with those observed using pfdhfr 59 Arg and
TABLE 2
Assessment of association between pfdhfr and pfdhps genotypes and
treatment outcome*
Genotype TF ACR OR (95% CI) Chi-square P
Quintuple mutants 12 39
Non-quintuple 43 289 2.1 (0.94–4.48) 4.0 0.045
Total 55 328
* pfdhfr = Plasmodium falciparum dihydrofolate reductase; pfdhps  P. faciparum dihy-
dropteroate synthase. TF  Treatment failure; ACR  adequate clinical response; OR 
odds ratio; CI confidence interval, quintuple pfdhfr 108 Asn, 51 Ile, 59 Arg and pfdhps
437 Gly and 540 Glu.
TABLE 3
GFIs calculated by using different combinations of mutations in
pfdhfr and pfdhps as markers of SP resistance in five sentinel sites
in Tanzania*
Site Overall TF (%) GFITriple dhfr GFITriple + Double dhfr GFIDouble dhps
Butimba 7 2.1 9.64 2.76
Kyela 12 1.99 5.3 1
Masasi 6.8 1.98 5.7 0.6
Mkuzi 23.6 3.4 4.4 1.37
Mlimba 13.5 1.96 6.4 0.25
* TF  Treatment failure; GFI  genotype failure index (subscripts are markers used to
calculate the GFI). For definitions of other abbreviations, see Tables 1 and 2.
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pfdhps 540 Glu genotypes as markers for SP resistance in
Uganda (1.9)23 and Malawi (2.2).24 The GFIs observed in our
study imply that the prevalence of the triple pfdhfr mutant
genotype was 3.4 and 2 times higher than treatment failure
rates in high and moderate SP resistance sites, respectively. It
should be noted that the deviation observed in the former site
might limit the applicability of GFI-based models as tools for
monitoring SP resistance. This deviation may partly imply
that during the genesis of SP resistance, a plateau/saturation
point may be reached beyond which a further increase in the
prevalence of the triple pfdhfr mutant genotype produces
only a marginal decrease in in vivo SP treatment failure. It has
also been argued that differences in prevalence of the triple
pfdhfr mutant genotype among sites might only reflect the
duration and magnitude of SP use and not differences in SP
resistance.36 Therefore, to better understand the relationship
between mutations and treatment failure, we recommend
multi-sites community and health facility longitudinal studies
to be carried out. These studies should focus on exploring the
use of mutant genotypes in estimating resistance, rather than
predicting individual treatment failures. In addition, they
should be designed so as to allow controlling for confounders
such as age and parasite densities. The GFIs generated by
using other combinations of pfdhfr and pfdhps mutations
were highly variable. Thus, the role of these markers in moni-
toring SP resistance (in the GFI context) needs further inves-
tigation. In this study, the moderate resistance sites showed
no significant difference in the prevalence of the triple pfdhfr
mutant genotype, contrary to a previous report in which sites
with small differences in SP resistance showed major differ-
ences in pfdhfr genotypes.36 Instead, these sites showed
marked differences in the prevalence of double pfdhps mu-
tant genotypes. A high prevalence of triple pfdhfr and double
pfdhps point mutations haplotypes has also been observed in
northern Tanzania with significant interregional heterogene-
ity in allele frequency.37
The pfdhfr 164 Leu mutation has been detected in the Mu-
heza District in Tanzania, an area with high SP resistance, by
using yeast expression assays.38 However, this mutation was
not detected by the standard PCR-RFLP and/or sequencing
methods in the present and other studies conducted in the
same39 or other parts of Africa.40,41 Therefore, it has been
suggested that the pfdhfr 164 Leu mutant allele detected in
Tanzania represents only the normal baseline and nonfunc-
tional mutations of the pfdhfr gene that occur naturally dur-
ing DNA replication.39,40 Similar to another report from
Malawi,41 we did not detect the pfdhps 436 Ala/Phe, 581 Gly,
or 613 Thr/Ser mutations at any of our study sites. All of these
mutations that have not been detected in Africa are prevalent
in southeast Asia and South America.42 Interestingly, how-
ever, the pfdhps 436 mutation was detected in Kibaha, Tan-
zania.37 Studies on polymorphic microsatellite repeats in the
flanking regions of the pfdhfr and pfdhps genes in southern
Africa and southeast Asia suggest gene flow/selective sweep
rather than new mutations as the most likely means by which
SP resistance spreads.43,44 Therefore, the absence of these
alleles in areas such as Muheza, where antifolate antimalarials
have been used for a long time and resistance is high, suggests
that the southern African and southeast Asian parasite popu-
lations may have different evolutionary origins. This hypoth-
esis is yet to be verified. However, there will always be a
necessity to constantly monitor for parasites carrying the
pfdhfr 164 Leu alleles in sub-Saharan Africa because its ap-
pearance, through importation or otherwise, and subsequent
spread would compromise the useful therapeutic life (UTL)
of other alternative antimalarial drugs such as chlorproguanil-
dapsone.
These findings constitute the baseline data on SP efficacy
and prevalence of pfdhfr and pfdhps genotypes in Tanzania.
The clinical and molecular information gained from these
studies signal that SP may have a short UTL in Tanzania, the
basis for adoption of SP as an interim, first-line antimalarial
drug. Thus, there is a need to advocate for rational use of the
drug and conduct regular surveillance to monitor resistance
concurrent with accelerated evaluation of different alterna-
tive treatments, especially combination antimalarial thera-
pies. These data provide preliminary evidence suggesting that
the triple pfdhfr mutant genotype may form a suitable early
warning tool for increasing SP resistance in Tanzania. Further
studies need to be done, at both community and health facility
levels, to verify the usefulness of pfdhfr and pfdhps genotypes
in estimating SP resistance.
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